Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 4, 2008, Pages 647-652

  Stapleton, Stacie L ^a   Thompson, Patrick A ^a   Ou, Ching Nan ^a   Berg, Stacey L ^a   McGuffey, Leticia ^a   Gibson, Brian ^a   Blaney, Susan M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CSF penetration; Histone deacetylase inhibitor; Pharmacokinetics; Valproic acid

Indexed keywords

HISTONE DEACETYLASE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ENZYME INHIBITION; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ENZYME INHIBITORS; HALF-LIFE; HISTONE DEACETYLASES; MACACA MULATTA; VALPROIC ACID;

EID: 38049007956     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0519-3     Document Type: Article

References (15)

1. Blaney SM, Balis FM, Hegedus L, Heideman RL, McCully C, Murphy RF, Kelley JA, Poplack DG (1990) Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primates. Cancer Res 50:7915-7919
2. Lundberg B, Nergardh A, Boreus LO (1982) Plasma concentrations of valproate during maintenance therapy in epileptic children. J Neurol 228:133-141
3. Sztajnkrycer MD (2002) Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 40:789-801
4. Lindberger M, Tomson T, Wallstedt L, Stahle L (2001) Distribution of valproate to subdural cerebrospinal fluid, subcutaneous extracellular fluid, and plasma in humans: a microdialysis study. Epilepsia 42:256-261
5. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC (2005) Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4:1912-1922
6. Council NR (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington DC
7. D'Argenio DSA (1997) ADAPT II User's Guide: pharmacokinetic/ pharmacodynamic systems analysis software. Biomedical Simulations Resource, University of Southern California, Los Angeles
8. Wong H, Rurak DW, Kumar S, Kwan E, Abbott FS, Riggs KW (2001) Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. Drug Metab Dispos 29:664-675
9. Loscher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31-59
10. Muraszko K, Sung C, Walbridge S, Greenfield L, Dedrick RL, Oldfield EH, Youle RJ (1993) Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents. Cancer Res 53:3752-3757
11. Koch-Weser J, Sellers EM (1976) Binding of drugs to serum albumin (first of two parts). N Engl J Med 294:311-316
12. Mellett LB (1977) Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system. Cancer Treat Rep 61:527-531
13. Panomvana Na Ayudhya D, Suwanmanee J, Visudtibhan A (2006) Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children. Am J Ther 13:211-217
14. Rapeport WG, Mendelow AD, French G, MacPherson P, Teasdale E, Agnew E, Thompson GG, Brodie MJ (1983) Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosing. Br J Clin Pharmacol 16:365-369
15. Witt O, Schweigerer L, Driever PH, Wolff J, Pekrun A (2004) Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 43:181